TSP-2 Expressing MSCs for Cartilage Regeneration

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

The association of chondrogenic differentiation of stem cells with thrombospondin 1 (TSP-1), TSP-2, interleukin 17B receptor (IL-17BR), and heparin-binding epidermal growth factor-like growth factor (HB-EGF has not been proven, limiting therapeutic options for cartilage injuries and degenerative arthritis.

Innovation Solution

A composition comprising TSP-2, or cells expressing TSP-2, is used to stimulate chondrogenic differentiation of mesenchymal stem cells into chondrocytes, facilitated by a medium containing biocompatible polymers like hyaluronic acid, hydroxyapatite, or chitosan, to treat cartilage injuries and degenerative arthritis.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Object-affected harmful factors

If conventional therapies (anti-inflammatory agents, COX-2 inhibitors, hydrocortisone, glucosamine, chondroitin sulfate) are used to treat cartilage loss, then pain relief is achieved, but cartilage regeneration is not promoted and the disease progresses with time

Engineering Contradiction:

Improvecartilage lossVSAvoidpain relief duration

Core Design Contradiction:

Object-affected harmful factorsVSReliability

Solution Approach 1:

The patent converts the harmful effect of cartilage degradation into a beneficial process by using the patient's own joint fluid (which contains catabolic factors) to stimulate chondrogenic differentiation of mesenchymal stem cells. The joint fluid, normally associated with cartilage breakdown, is repurposed as a differentiation inducer that promotes cartilage regeneration rather than merely suppressing pain symptoms

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Solution Approach 2:

The therapy employs the patient's own joint fluid and mesenchymal stem cells (derived from their own bone marrow or adipose tissue) to treat their own cartilage defect. The system uses self-produced factors (TSP-2, IL-17BR, HB-EGF) to drive regeneration, eliminating the need for external growth factors or synthetic materials

Inventive Principle:

Principle #25Self-service

2Productivity

If TSP-2, IL-17BR, and HB-EGF are expressed in mesenchymal stem cells to promote chondrogenic differentiation, then cartilage regeneration is enhanced, but the mechanism and effectiveness were not previously proven

Engineering Contradiction:

Improvechondrogenic differentiation efficiencyVSAvoidmechanism knowledge

Core Design Contradiction:

ProductivityVSLoss of information

Solution Approach 1:

The patent establishes a feedback loop where mesenchymal stem cells express specific proteins (TSP-2, IL-17BR, HB-EGF) in response to joint fluid stimulation, which then promotes their chondrogenic differentiation. The expression of these proteins is upregulated by the joint fluid environment, creating a self-reinforcing cycle that enhances cartilage regeneration capability

Inventive Principle:

Principle #23Feedback

Solution Approach 2:

The patent identifies and utilizes specific protein expression parameters (TSP-2, IL-17BR, HB-EGF) as key drivers of chondrogenic differentiation. By measuring and controlling the expression levels of these proteins in mesenchymal stem cells, the therapy optimizes the differentiation process and enhances cartilage regeneration effectiveness

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentUS9408892B2Treating cartilage defect with UCB-MSC expressing TSP-2

Publication Date: 2016.08.09 MEDIPOST

AI summary

Thrombospondin 1 (TSP-1), TSP-2, interleukin 17B receptor (IL-17BR) and heparin-binding epidermal growth factor-like growth factor (HB-EGF) associated with stem cell activity and use thereof.